original articlesurogenital tumorsPhase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
urogenital tumors
Under an Elsevier user license
open archive
Keywords
chemotherapy
chromogranin A
metastatic castration-resistant prostate cancer
neuron-specific enolase
visceral metastases
Cited by (0)
- †
Deceased.
Copyright © 2011 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.